REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Peptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) Doai > Heavy Metal Containing (e.g., Hemoglobin, Etc.) Heavy Metal Containing (e.g., Hemoglobin, Etc.)Heavy Metal Containing (e.g., Hemoglobin, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.03/01/07 - 20070049517 - Use of hyperpolymeric hemoglobin for the treatment of pulmonary edema This invention relates to the use of hypo-oncotic aqueous solutions of molecularly dispersed chemically modified high molecular weight crosslinked hemoglobins, namely so-called hemoglobin hyperpolymers, to prepare agents for the symptomatic, primarily life-saving treatment of acute pulmonary edema. Administration in particular is intravascular. Surprisingly, additive administration can be performed since according ... 02/22/07 - 20070042937 - Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers The present invention provides methods for increasing endogenous globin expression in a subject, specifically γ-globin expression. The invention also provides compounds and medicaments for use in the methods. The methods are particularly useful for increasing fetal hemoglobin production in a subject, and can be used to treat various disorders, e.g., ... 02/01/07 - 20070027064 - Pharmaceutical compositions for inhibiting metal ion dependent enzymatic activity and methods for the use thereof Methods for inhibiting metalloprotease activity; treating a pathological condition influenced by the action of MMP; treating a pathological condition influenced by cyclooxygenases, endonucleases, metallopepitidases and 5-epoxigenase; treating a pathological condition for which the presence of a metal ion is required; inhibiting the lethal factor produced by toxigenic strains of anthrax; ... 01/18/07 - 20070015689 - Complexation of metal ions with polypeptides Formulations and methods are provided for improving the stability upon exposure to aqueous media of polypeptides present in non-aqueous suspension vehicles. In particular aspects of the invention, formulations are provided that comprise a complex of a metal ion and a polypeptide suspended in a non-aqueous, biocompatible suspension vehicle. Aggregation of ... 01/18/07 - 20070015688 - Method for screening for inhibitors of alzheimer's disease This invention relates to compounds which have the ability to act as agonists for the binding of divalent copper ions to amyloid precursor protein (APP) and to methods of identifying such compounds by using the three-dimensional structure of the copper-binding domain of APP. ... 01/11/07 - 20070010427 - Use of one or more metal carriers to selectively kill mammalian cells Compositions and methods for decreasing the viability of cells, particularly aberrant non-healthy cells, and most particularly cancer cells, are disclosed. The primary agent that causes cell death is a toxic metal atom or ion. Embodiments of the invention provide compositions and methods to ensure that the toxic metal is directed ... 01/11/07 - 20070010426 - Composition for preventing and treating cardiovascular disorders A composition for preventing and treating cardiovascular disorders is disclosed. The composition includes the lactoferrin and a trivalent chromium compound. The trivalent chromium compound of the present invention is selected from a group consisting of chromium (III) chloride hexahydrate, chromium (III) chloride, chromium (III) acetate, chromium (III) sulfate, chromium picolinate, ... 01/04/07 - 20070004617 - Compositions and methods for treating or preventing overweight or obesity with zinc-charged protein fragments Compositions and methods for treating or preventing, for example, overweight or obesity are provided. Compositions provided comprise zinc-charged, protease digested serum or milk proteins. Compositions are administered in a therapeutically effective amount to treat or prevent, for example, overweight or obesity. ... 01/04/07 - 20070004616 - Glp-1 pharmaceutical compositions The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues. ... 12/21/06 - 20060287222 - Polymerized hemoglobin solutions having reduced amounts of tetramer and method for preparing A substantially tetramer free hemoglobin solution and a method for producing a substantially tetramer free hemoglobin solution. The method includes polymerizing a solution of hemoglobin, treating the polymerized hemoglobin solution to partially degrade the polymer to tetramer and removing tetramer from the hemoglobin solution. ... 12/07/06 - 20060276374 - Use of an agent that restores tissue perfusion and oxygenation The presently disclosed subject matter provides methods for increasing perfusion in hypoxic regions of tissues in subjects. Also provided are methods for treating diseases and/or disorders associated with hypoxia in subjects, methods for increasing sensitivity of tumors to radiation and/or chemotherapy treatments, methods for delaying tumor growth in subjects, and ... 11/23/06 - 20060264357 - Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals The present invention provides a method of treating a human subject to prevent leakage of serum proteins from capillary endothelial junctions during a period of increased capillary permeability and at the same time preventing the harmful effects of free radicals on capillaries and surrounding tissues. The method comprises administering to ... 11/16/06 - 20060258563 - Novel hemepeptide A novel heme peptide and a method for producing the same are disclosed. The invention provides a peptide with a potent NO-scavenging ability which can be used in capturing/quantifying NO and can be used as a diagnostic agent, prophylactic agent or therapeutic agent for diseases in which NO is involved, ... 11/09/06 - 20060252671 - Forming iron nitrosyl hemoglobin Contrary to current opinion that nitrite in general oxidizes hemoglobin with elimination of active nitric oxide, deoxygenated hemoglobin reacts with low concentration inorganic nitrite to produce very stable iron nitrosyl hemoglobin which on delivery into the body is converted to a hemoglobin capable of nitric oxide delivery and provides vasodilator ... 10/19/06 - 20060234915 - Compositions and methods for delivering carbon monoxide (co) and nitric oxide (no) to tissue using heme proteins as carriers The present invention relates to compositions and methods for delivering nitric oxide (NO) or carbon monoxide (CO) to cells using heme proteins as carriers. In one embodiment, the present invention relates to the use of modified hemoglobin to deliver NO or CO to cells ... 09/28/06 - 20060217291 - Radiosensitizer There is provided a radiosensitizer containing an iron compound, more specifically, a radiosensitizer containing an iron compound selected from an inorganoiron compound, such as iron chloride, iron oxide, iron hydroxide, and iron sulfate; and an organoiron compound, such as saccharated ferric oxide, iron citrate, iron gluconate, chondroitin sulfate/iron colloid, cideferron, ... 09/21/06 - 20060211601 - Nitrosated and nitrosylated heme proteins Nitrosylation of proteins and amino acid groups enables selective regulation of protein function, and also endows the proteins and amino acids with additional smooth muscle relaxant and platelet inhibitory capabilities. Thus, the invention relates to novel compounds achieved by nitrosylation of protein thiols. Such compounds include: S-nitroso-heme proteins, S-nitroso-t-PA, S-nitroso-cathepsin; ... 09/14/06 - 20060205634 - Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease The present invention relates to methods of using lactoferrin (LF) to reduce circulating levels of cholesterol and vascular inflammation, in order to treat, prevent or reduce the incidence of atherosclerosis and cardiovascular disease. ... 08/24/06 - 20060189513 - Lactoferrin in the treatment of diabetes mellitus The present invention relates to methods of using a composition of lactoferrin for the treatment of diabetes mellitus as manifested by a reduction in the levels of serum glucose, blood pressure, obesity, or glycosylated hemoglobin (HbA1c). ... 08/17/06 - 20060183671 - Treatment of anemia The present invention relates to a method for the treatment of anemia based on the administration of the product of growth arrest-specific gene 6 (Gas6), its mutants, variants, active derivatives and the physiological tolerated salts of said Gas6 derivatives or of a group of biologically active substances inducing a GAS6 ... 08/03/06 - 20060172924 - Methods to enhance hemodynamic stability using oxygen carrying compositions The present invention relates to methods for enhancing the hemodynamic stability of an individual undergoing surgery by administering a composition comprising a hemoglobin-based oxygen carrier. In one embodiment, the present invention relates to the use of polyalkylene oxide modified hemoglobins with reduced cooperativity and a high oxygen affinity to enhance ... 07/27/06 - 20060166864 - Methods for modulating telomerase activity Disclosed herein are engineered zinc finger proteins which bind to telomeric structures; methods for their design, synthesis and use; and cells comprising a telomere-binding zinc finger protein. Methods for modulating telomerase activity using telomere-binding zinc finger proteins are also provided. ... 07/27/06 - 20060166863 - Inhibitor and stimulator of stem cell proliferation and uses thereof Disclosed and claimed are methods for the isolation and use of stem cell modulating factors for regulating stem cell cycle and for accelerating the post-chemotherapy peripheral blood cell recovery. Also disclosed and claimed are the inhibitors and stimulators of stem cell proliferation. ... 07/27/06 - 20060166862 - Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation An agent, composition and method for the treatment, prophylaxis and/or diagnosis of proliferative disorders, which is highly and efficiently absorbed at the site of abnormal cellular proliferation is disclosed. ... 07/27/06 - 20060166861 - Inclusion compound of porphyrin metal complex and albumin where R1 is a cyclohexyl group or the like; R2 represents a substituent; M represents a transition metal atom or metal ion belonging to Groups 6 to 10 of the periodic table; X− represents a halogen ion; and the number of X− is obtained by subtracting 2 from a valence ... 07/27/06 - 20060166860 - Zinc transporter compositions for the treatment of cardiovascular diseases The present invention relates to the use of ZnT-1, originally described as a zinc transporter, in the regulation of L-type calcium channels (LTCC). In this study, the inventors have unexpectedly demonstrated that ZnT-1 physically interacts with LTCC, regulating its function. Most importantly, the inventors have shown that ZnT-1 can regulate ... 07/20/06 - 20060160724 - Preserving a hemoglobin blood substitute with a transparent overwrap The invention relates to a method for preserving the stability of a hemoglobin blood substitute comprising maintaining the hemoglobin blood substitute in an atmosphere substantially free of oxygen. The method for preserving the deoxygenated hemoglobin blood substitute comprises maintaining the deoxygenated blood substitute in an oxygen barrier film overwrap package, ... 07/20/06 - 20060160723 - Glycoproteins having lipid mobilising properties and therapeutic applications thereof A biologically active lipid mobilising agent for use in therapy is disclosed which has the properties and characteristics of a Zn-α2-glycoprotein, or of a fragment thereof having an apparent molecular mass Mr greater than 6.0 kDa as determined by gel exclusion chromatography. Methods of isolation and purification from biological material ... 07/06/06 - 20060148677 - Chondrogenesis stimulator There are provided a chondrogenesis stimulator containing MTf, a chondrogenic differentiation suppressing agent containing an MTf antagonist, a screening method for obtaining an MTf activating agent, an MTf activating agent obtained by the screening method, a chondrogenesis stimulator containing an MTf activating agent as obtained by the screening method, and ... 06/29/06 - 20060142183 - Method and composition for treatment and/or prevention of antibiotic-resistant microorganism infections The present invention related to a new composition, use and method to improve the cure of infections caused by antibiotic resistant microbial pathogens, in particular beta-lactam resistant microorganisms. Lactoferrin (LF) or Lactoferricin (LFC) can be administrated alone or in combination with antibiotic to affect growth, physiology and morphology of targeted ... 06/22/06 - 20060135407 - Phosphoprotein preparations for bioactive metal ion delivery and teeth remineralisation The invention provides, in one aspect, compositions for delivering a bioactive metal ion to a mammal, the compositions comprising (a) an effective amount of a source of the bioactive metal ion, (b) a phosphoprotein preparation obtained by partially cross linking a partial hydrolysate of casein or a caseinate, and (c) ... 06/15/06 - 20060128606 - Fibrils An amyloid fibril substantially free of other protein is disclosed. Also disclosed are processes for preparing the fibril, and methods and uses of the fibril particularly in connection with treating diabetes, blood clotting disorders, cancer and/or heart disease. ... 06/08/06 - 20060122100 - Melanin extinguisher wherein M denotes a metal, and R denotes hydroxyl, O-lower alkyl, an amine bonded at N, an amino acid bonded at N, or a peptide bonded at N, or a pharmacologically acceptable salt thereof. ... 05/25/06 - 20060111275 - Size enhanced hemoglobins: surface decoration and crosslinking of the protein with polyoxy alkylene glycols Novel modified hemoglobins comprising polyalkylene glycols and novel methods for making those hemoglobins are provided. One group of modified hemoglobins comprise polyalkylene glycols bonded to the hemoglobin with an amide linkage at Glu-43(β). Additional polyalkylene glycols can also be bonded to the Glu-22(β) and/or the Asp-47(β). These hemoglobins are made ... 03/09/06 - 20060052287 - Polyethylene glycol - peptide copper complexes and compositions and methods related thereto This invention relates to compositions comprising polyethylene glycol molecules coupled to peptide copper complexes, and, additionally, to such compositions formulated for use as pharmaceutical and cosmetic products, as well as to medical devices that comprise such compositions. ... 03/09/06 - 20060052286 - Factor vii conjugates for selectively treating neovascularization disorders Methods and compositions are provided for the treatment of diseases such as exudative macular degeneration, diabetic retinopathy, retinopathy of prematurity, choroidal neovascularization, retinal neovascularization, iris neovascularization, corneal neovascularization, ocular tumors, and other disorders of the eye, cancer, and inflammatory disorders. The method involves administering a conjugate, referred to as fVIIPD, ... 02/09/06 - 20060030519 - Composition for reducing blood lipids A composition for reducing the blood lipids is disclosed. The composition includes the lactoferrin and a trivalent chromium compound. The trivalent chromium compound of the present invention is selected from a group consisting of chromium (III) chloride hexahydrate, chromium (III) chloride, chromium (III) acetate, chromium (III) sulfate, chromium picolinate, chromium ... 01/26/06 - 20060019876 - Targeted delivery of bioaffecting compounds for the treatment of cancer A homogeneous conjugate for targeting and treating diseased cells wherein the conjugate comprises an anti-cancer drug and a targeting protein, wherein said anti-cancer drug is selected from the group consisting of heat sensitizers, photosensitizers and apoptosis inducing compounds, a method for making such a conjugate, and methods for using the ... 01/26/06 - 20060019875 - Autologous coatings for implants A hydrocephalus shunt having an anti-inflammatory coating applied to at least the outside surface of the ventricular catheter. Such coatings are also applicable to other medical devices or implants. ... 01/19/06 - 20060014671 - Stabilized hemoglobin solutions A hemoglobin solution packaged in a flexible oxygen-impermeable container system. The container system includes a multi-layer film having at least a product contact layer, an oxygen and moisture barrier layer and an exterior layer. The flexible container system further includes an interface port for filling the flexible container with the ... 01/05/06 - 20060003923 - Porphyrin compound, albumin inclusion compound thereof and artificial oxygen carrier Also disclosed are a porphyrin metal complex-albumin inclusion compound having a porphyrin compound, in which M denotes Fe or Co, included in albumin, and an artificial oxygen carrier containing the porphyrin metal complex-albumin inclusion compound as an active component. ... 01/05/06 - 20060003922 - Spinner preparation machine and cavity resonator The present invention relates to the treatment of disorders using heme oxygenase-1 and heme degradation products. ... 12/22/05 - 20050282739 - Metallopeptide compounds Metallopeptides with a sequence of a biologically active alpha-melanocyte stimulating hormone (α-MSH), gamma-melanocyte stimulating hormone (γ-MSH), or bombesin sequence of length n residues, wherein a residue including a nitrogen atom and sulfur atom each available for complexation to a metal ion is inserted at any position from between the two ... 12/22/05 - 20050282738 - Alpha 1-acid glycoprotein, alpha 2-hs glycoprotein, alpha 1-antitrypsin, and fragments thereof induce apoptosis in cancer cell lines This invention characterizes the selective apoptotic activity of specially prepared zinc charged alpha 1-acid glycoprotein, alpha 2-HS glycoprotein, and alpha 1-antitrypsin. These proteins cause apoptosis in cancer cells while leaving normal cells intact. In addition, active fragments of zinc charged alpha 1-acid glycoprotein and alpha 2-HS glycoprotein, whether manufactured from ... 12/01/05 - 20050267015 - Method of treatment and composition for inhibiting the production of toxic free radical and reactive oxygen species using metalloproteins found in bacteria Compositions and methods for treating, reducing the risk of, or slowing the onset of a neurological disorder or pathological condition in a subject are provided. An inhibitor of the formation of free radical or reactive oxygen species is administered in an effective amount to the subject and the inhibitor prevents ... 10/27/05 - 20050239686 - Methods and compositions for optimization of oxygen transport by cell-free systems Compositions, and methods of use thereof, for use as blood substitute products comprise aqueous mixtures of oxygen-carrying and non-oxygen carrying plasma expanders and methods for the use thereof. The oxygen-carrying component may consist of any hemoglobin-based oxygen carrier, while the non-oxygen carrying plasma expander my consist of any suitable diluent. ... 10/20/05 - 20050233948 - Drug complex for treatment of metastatic prostate cancer A drug complex for delivery of a drug or other agent to a target cell, comprising a targeting carrier molecule which is selectively distributed to a specific cell type or tissue containing the specific cell type; a linker which is acted upon by a molecule which is present at an ... 10/13/05 - 20050227912 - Blood substitutes The functional characteristics of heme proteins can be modified to produce hemoglobins that can be used as blood substitutes in different therapeutic applications. Stable polymers of tetrameric hemoglobin, and of myoglobin molecules, are provided for use in the blood substitutes. ... 10/06/05 - 20050222007 - Pharmaceutical composition and method for treatment or prevention of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences Disclosed is the use of a substance selected from the group consisting of human apo-lactoferrin and/or peptides derivable from human lactoferrin and/or natural metabolites of human lactoferrin and/or functionally equivalent analogues of human apo-lactoferrin for the production of a pharmaceutical composition for treatment and/or prevention of a vascular disease and/or ... 09/22/05 - 20050209131 - Composition containing peptides complexed with a copper ion The present invention relates to compositions comprising peptides complexed with a copper ion. In one embodiment, the composition comprises a copper peptide and a basic amino acid. In another embodiment, the composition is an emulsion composition comprising a copper peptide and a non-ionic emulsifier, wherein the composition is substantially free ... 09/22/05 - 20050209130 - Compositions and methods for treatment of rosacea A method for treating rosacea of the skin of a patient employs topically applying to the affected skin a composition comprising at least one peptide copper complex. In other embodiments, the present invention is directed to such a method where the composition used therefor further comprises certain disclosed active agents, ... 09/22/05 - 20050209129 - Methods and kits for purifying his-tagged proteins Disclosed are methods of separating a target molecule from a non-target molecule using zinc- or cobalt-charged solid supports. ... 09/08/05 - 20050197282 - Compositions and methods for treatment of psoriasis A method for treating psoriasis of the skin of a patient employs topically applying to the affected skin a composition comprising at least one peptide copper complex. In other embodiments, the present invention is directed to such a method where the composition used therefor further comprises certain disclosed active agents, ... 09/08/05 - 20050197281 - Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins A kit comprising an erythropoietin and a modified hemoglobin is disclosed. ... 08/11/05 - 20050176624 - Organometallic complexes as singlet oxygen sensitizers A series of organometallic complexes and the singlet oxygen sensitization properties of these complexes are provided. Complexes with acetylacetonate ligands give singlet oxygen quantum yields near unity, whether exciting the ligand-based state or the lowest energy excited state (MLCT+3LC). The singlet oxygen quenching rates for these β-diketonate complexes are small, ... 07/28/05 - 20050164915 - Compositions for oxygen transport comprising a high oxygen affinity modified hemoglobin The present invention relates to blood products, and more particularly to compositions comprising a modified oxygenated hemoglobin having a high affinity for oxygen and methods for making such compositions. Such compositions according to the present invention have better stability to autooxidation and superior oxygen carrying characteristics. ... 07/28/05 - 20050164914 - Metallopeptide compositions for treatment of sexual dysfunction Metallopeptide compositions are provided for treatment of sexual dysfunction in mammals, including male sexual dysfunction, such as erectile dysfunction, and female sexual dysfunction. The metallopeptides include at least one, and preferably two, aromatic amino acid side chain moieties, and are further characterized in that the metallopeptides preferably do not bind ... 07/28/05 - 20050164913 - Disinfecting composition The invention relates to compositions used for disinfecting and applicable in the national economy, medicine, and laboratories of all types. The composition comprises a chelating metal complex compound comprising a monodentate, bidentate, or polydentate ligand that exhibits affinity to hydrogen ion, an ionogenic surfactant, and a solvent. The preparation displays ... 07/21/05 - 20050159340 - Lactoferrin for age related disorders in humans The method of the present invention provides a novel use of lactoferrin to modulate the molecular events during development of age-related disorders in humans. More specifically, the present invention is directed to the use of lactoferrin to treat or prevent autoimmune, neurodegenerative and immune hypersensitivity disorders, and its use for ... 07/21/05 - 20050159339 - Pegylated non-hypertensive hemoglobins, methods of preparing same, and uses thereof The present invention provides pegylated hemoglobins comprising a thiocarbamoyl-phenyl-polyethylene glycol (PEG) attached to hemoglobin, and comprising a polyethylene glycol (PEG) attached to hemoglobin by an acyl group. The invention also provides methods of preparing pegylated hemoglobins using isothiocyanato phenyl carbamate of PEG and using isothiocyanato phenyl di-PEG carbamate. The invention ... 07/14/05 - 20050153875 - Ultrapure transferrin for pharmaceutical compositions The present invention relates to an ultrapure human transferrin, and to methods for manufacturing the ultrapure transferrin. The transferrin may be holo-, apo- or at any desired degree of iron saturation. The invention further relates to the use of ultrapure transferrin as the protein moiety of conjugates, and to pharmaceutical ... 06/16/05 - 20050130880 - Hypoglycemic agent A zinc(II) complex which is lowly toxic, has high insulin-like activity, and is effectively usable as a hypoglycemic agent for the prevention or treatment of diabetes; a hypoglycemic agent containing the complex; a medicinal preparation which contains the complex and is useful as a preventive/remedy for diabetes; and a food ... 06/02/05 - 20050119162 - Novel analgesics The object of this invention is to provide a novel pharmaceutical composition for getting rid of pains and anxiety in patients. This invention relates to a pharmaceutical composition containing lactoferrin as an active ingredient. The composition of this invention is useful for treatment of at least one disease or condition ... 06/02/05 - 20050119161 - Methods and compositions for oxygen transport comprising an oxygen carrier and a crystalloid in hypertonic solution The present invention relates to blood product compositions, and more particularly to compositions comprising a modified hemoglobin and a crystalloid in an aqueous diluent. The present invention also relates to such blood product compositions which are formulated as hypertonic solutions to provide for low volume rapid restoration of hemodynamic parameters ... ### FreshPatents.com Support |